Australien - engelska - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tramadol hydrochloride, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: sucrose; propylene glycol; sodium cyclamate; saccharin sodium; purified water; glycerol; ethoxylated hydrogenated castor oil; mint oil dementholised; potassium sorbate; flavour - tramal oral drops are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - itraconazole, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: propylene glycol; hydroxypropylbetadex; saccharin sodium; purified water; caramel; sorbitol solution (70 per cent) (non-crystallising); sodium hydroxide; hydrochloric acid; flavour - sporanox oral solution is indicated for: * the treatment of oral and/or oesophageal candidiasis in hiv-positive or other immunocompromised patients. * prophylaxis of fungal infections in neutropenic patients.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 26.86 mg/ml (equivalent: cefaclor, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - aclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. aclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of aclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - pregabalin, quantity: 20 mg/ml - oral liquid, solution - excipient ingredients: sucralose; monobasic sodium phosphate monohydrate; purified water; methyl hydroxybenzoate; dibasic sodium phosphate; flavour - pregabalin-aft is indicated for the treatment of neuropathic pain in adults.,pregabalin-aft is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - codeine phosphate hemihydrate, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: glycerol; propylene glycol; sucrose; purified water; potassium sorbate; hydrochloric acid; sodium hydroxide; methyl hydroxybenzoate; propyl hydroxybenzoate; ethyl hydroxybenzoate; butyl hydroxybenzoate; isobutyl hydroxybenzoate - relief of unproductive, dry and intractable coughs associated with colds and flu.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - codeine phosphate hemihydrate, quantity: 5 mg/ml - oral liquid - excipient ingredients: glycerol; propylene glycol; purified water; sucrose; methyl hydroxybenzoate - relief of unproductive, dry and intractable coughs associated with colds and flu relief of unproductive, dry and intractable coughs associated with colds and flu.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - fexofenadine hydrochloride, quantity: 6 mg/ml - oral liquid, suspension - excipient ingredients: xanthan gum; butyl hydroxybenzoate; propyl hydroxybenzoate; titanium dioxide; disodium edetate; purified water; monobasic sodium phosphate monohydrate; poloxamer; xylitol; propylene glycol; dibasic sodium phosphate heptahydrate; sucrose; flavour - relief of symptoms associated with seasonal allergic rhinitis and allergic rhinitis in adults and children from 2 years of age. relief of symptoms associated with urticaria in adults and children from 6 months of age.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - erythromycin ethyl succinate, quantity: 468 mg (equivalent: erythromycin, qty 400 mg) - oral liquid, powder for - excipient ingredients: sorbitol; propylene glycol alginate; sodium citrate dihydrate; erythrosine; aspartame; sodium benzoate; colloidal anhydrous silica; flavour - streptococcus pyogenes (group a beta-haemolytic streptococcus). upper and lower respiratory tract, skin and skin structure infections of mild to moderate severity. when oral medication is given, patient must comply with the prescribed regimen. therapeutic dose should be administered for at least 10 days. alpha haemolytic streptococci (viridans group). no controlled clinical efficacy trials have been conducted, however oral erythromycin has been suggested by the american heart association and the american dental association for use in bacterial endocarditis prophylaxis prior to dental/surgical procedures of the upper respiratory tract in penicillin-hypersensitive patients with a history of rheumatic, congenital or other acquired valvular heart disease. erythromycin is unsuitable prior to genitourinary or gastrointestinal tract surgery. staphylococcus aureus. acute infections of skin and skin structure of mild to moderate severity. bacterial resistance may emerge during treatment, hence cultures and sensitivity

Australien - engelska - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - erythromycin ethyl succinate, quantity: 234 mg (equivalent: erythromycin, qty 200 mg) - oral liquid, powder for - excipient ingredients: sorbitol; propylene glycol alginate; sodium citrate dihydrate; erythrosine; aspartame; sodium benzoate; colloidal anhydrous silica; flavour - streptococcus pyogenes (group a beta-haemolytic streptococcus). upper and lower respiratory tract, skin and skin structure infections of mild to moderate severity. when oral medication is given, patient must comply with the prescribed regimen. therapeutic dose should be administered for at least 10 days. alpha haemolytic streptococci (viridans group). no controlled clinical efficacy trials have been conducted, however oral erythromycin has been suggested by the american heart association and the american dental association for use in bacterial endocarditis prophylaxis prior to dental/surgical procedures of the upper respiratory tract in penicillin-hypersensitive patients with a history of rheumatic, congenital or other acquired valvular heart disease. erythromycin is unsuitable prior to genitourinary or gastrointestinal tract surgery. staphylococcus aureus. acute infections of skin and skin structure of mild to moderate severity. bacterial resistance may emerge during treatment, hence cultures and sensitivity

Australien - engelska - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenoxymethylpenicillin benzathine, quantity: 40.27 mg/ml (equivalent: phenoxymethylpenicillin, qty 30 mg/ml) - oral liquid, suspension - excipient ingredients: sodium propyl hydroxybenzoate; sodium methyl hydroxybenzoate; butylated hydroxyanisole; polysorbate 80; xanthan gum; sucrose; purified water; sodium citrate dihydrate; potassium sorbate; citric acid; flavour - treatment of mild to moderately severe infections due to penicillin sensitive staphylococci, pneumococci, gonococci and haemolytic streptococci infections. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. for prophylactic use in recurrent streptococcal infections including the prevention of recurrence following rheumatic fever and/or sydenham's chorea and to prevent bacterial endocarditis in patients with rheumatic fever and/or congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation. note: oral penicillin should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower intestinal tract surgery, sigmoidoscopy or complications of childbirth.